Athersys (ATHX) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ATHX vs. NBY, SPRB, AFMD, VCNX, GRAY, OGEN, PTN, GRTX, ONCT, and BPTHShould you be buying Athersys stock or one of its competitors? The main competitors of Athersys include NovaBay Pharmaceuticals (NBY), Spruce Biosciences (SPRB), Affimed (AFMD), Vaccinex (VCNX), Graybug Vision (GRAY), Oragenics (OGEN), Palatin Technologies (PTN), Galera Therapeutics (GRTX), Oncternal Therapeutics (ONCT), and Bio-Path (BPTH). Athersys vs. Its Competitors NovaBay Pharmaceuticals Spruce Biosciences Affimed Vaccinex Graybug Vision Oragenics Palatin Technologies Galera Therapeutics Oncternal Therapeutics Bio-Path Athersys (NASDAQ:ATHX) and NovaBay Pharmaceuticals (NYSE:NBY) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability. Do insiders & institutionals have more ownership in ATHX or NBY? 19.4% of Athersys shares are owned by institutional investors. Comparatively, 23.3% of NovaBay Pharmaceuticals shares are owned by institutional investors. 0.0% of Athersys shares are owned by insiders. Comparatively, 0.1% of NovaBay Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend ATHX or NBY? NovaBay Pharmaceuticals has a consensus target price of $0.85, suggesting a potential upside of 35.14%. Given NovaBay Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe NovaBay Pharmaceuticals is more favorable than Athersys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NovaBay Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ATHX or NBY more profitable? Athersys has a net margin of 0.00% compared to NovaBay Pharmaceuticals' net margin of -102.72%. Athersys' return on equity of 0.00% beat NovaBay Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets AthersysN/A N/A -223.03% NovaBay Pharmaceuticals -102.72%-7,293.78%-158.41% Which has preferable earnings and valuation, ATHX or NBY? NovaBay Pharmaceuticals has higher revenue and earnings than Athersys. NovaBay Pharmaceuticals is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAthersys$146K0.00-$72.53M-$2.03N/ANovaBay Pharmaceuticals$9.78M0.37-$9.64M-$53.72-0.01 Does the media refer more to ATHX or NBY? In the previous week, Athersys and Athersys both had 1 articles in the media. Athersys' average media sentiment score of 0.00 equaled NovaBay Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athersys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NovaBay Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, ATHX or NBY? Athersys has a beta of -0.9, indicating that its stock price is 190% less volatile than the S&P 500. Comparatively, NovaBay Pharmaceuticals has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. SummaryNovaBay Pharmaceuticals beats Athersys on 9 of the 13 factors compared between the two stocks. Get Athersys News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHX vs. The Competition Export to ExcelMetricAthersysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$833K$790.73M$5.53B$9.05BDividend YieldN/A4.84%5.24%4.03%P/E Ratio0.001.1327.5220.22Price / SalesN/A226.97421.02118.64Price / CashN/A23.4436.8958.07Price / BookN/A6.298.045.67Net Income-$72.53M-$27.73M$3.18B$249.13M Athersys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHXAthersysN/AN/AN/AN/A$833K$146K0.0024NBYNovaBay Pharmaceuticals2.0787 of 5 stars$0.57flat$0.85+49.1%-71.0%$3.32M$9.78M-0.0130SPRBSpruce Biosciences2.2083 of 5 stars$0.07flat$1.75+2,400.0%-87.2%$2.96M$4.91M-0.0720AFMDAffimed2.9925 of 5 stars$0.18-34.9%$3.62+1,895.9%-96.4%$2.92M$877K0.00200Gap DownHigh Trading VolumeVCNXVaccinexN/A$0.78+9.9%N/A-89.1%$2.76M$388K-0.0240GRAYGraybug VisionN/A$1.64-3.0%N/A-62.2%$2.58MN/A-0.9527High Trading VolumeOGENOragenics0.2206 of 5 stars$3.57-2.3%N/A-95.1%$2.55M$40K-0.505PTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading VolumeGRTXGalera Therapeutics0.2939 of 5 stars$0.03-1.1%N/A-78.7%$2.09MN/A-0.0830Gap DownONCTOncternal Therapeutics1.7373 of 5 stars$0.53flat$10.00+1,799.0%N/A$1.56M$790K-0.0530Positive NewsBPTHBio-Path2.5844 of 5 stars$0.19-2.3%$20.00+10,589.5%-90.4%$1.55MN/A0.0010Gap Down Related Companies and Tools Related Companies NovaBay Pharmaceuticals Competitors Spruce Biosciences Competitors Affimed Competitors Vaccinex Competitors Graybug Vision Competitors Oragenics Competitors Palatin Technologies Competitors Galera Therapeutics Competitors Oncternal Therapeutics Competitors Bio-Path Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athersys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athersys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
